Abstract
Childhood atopic dermatitis is a disorder with considerable social and financial costs. Consideration of these costs is increasingly important in view of the growing prevalence of atopic dermatitis, particularly in developed countries over recent decades. The family stress related to the care of children with moderate or severe atopic dermatitis is significantly greater than that of the care of children with type 1 diabetes mellitus. The factors contributing to family stress include sleep deprivation, loss of employment, time taken for care of atopic dermatitis and financial costs. The financial costs for the family and community include medical and hospital direct costs of treatments and indirect costs from loss of employment. There are many interventions utilised in the treatment of childhood atopic dermatitis which involve not only medical practitioners but nurses, pharmacists, dieticians, psychologists and purveyors of so-called alternative therapies such as naturopathy, aromatherapy and bioresonance, all of which contribute to the financial burdens on the parents and the community. It is possible that appropriate interventions directed to reducing trigger factors might produce worthwhile savings, although the cost benefit of these measures has not been demonstrated. In conclusion, atopic dermatitis should not be regarded as a minor skin disorder but as a condition which has the potential to be a major handicap with considerable personal, social and financial consequences both to the family and the community.
Similar content being viewed by others
References
Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 1998; 351: 1225–32
Castles I. 1989–90 National health survey summary of results. Canberra: Australian Bureau of Statistics, 1991
Asher MI, Barry D, Clayton T, et al. The burden of symptoms of asthma, allergic rhinoconjunctivitis and atopic eczema in children and adolescents in six New Zealand centres: ISAAC Phase One. N Z Med J 2001; 114: 114–20
Schultz Larsen F, Diepgen T, Svensson A. The occurrence of atopic dermatitis in north Europe: an international questionnaire study. J Am Acad Dermatol 1996; 34: 760–4
Tay YK, Kong KH, Khoo L, et al. The prevalence and descriptive epidemiology of atopic dermatitis in Singapore school children. Br J Dermatol 2002; 146: 101–6
Schultz Larsen F. Atopic dermatitis: a genetic-epidemiologic study in a population-based twin sample. J Am Acad Dermatol 1993; 28: 719–23
Butland BK, Strachan DP, Lewis S, et al. Investigation into the increase in hay fever and eczema at age 16 observed between the 1958 and 1970 British birth cohorts. BMJ 1997; 315: 717–21
Williams H, Robertson C, Stewart A, et al. Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood. J Allergy Clin Immunol 1999; 103: 125–38
Su JC, Kemp AS, Varigos GA, et al. Atopic eczema: its impact on the family and financial cost. Arch Dis Child 1997; 76: 159–62
Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1989; 144: 13–4
Daud LR, Garralda ME, David TJ. Psychosocial adjustment in preschool children with atopic eczema. Arch Dis Child 1993; 69: 670–6
Lawson V, Lewis-Jones MS, Finlay AY, et al. The family impact of childhood atopic dermatitis: the Dermatitis Family Impact Questionnaire. Br J Dermatol 1998; 138: 107–13
Reid P, Lewis-Jones MS. Sleep difficulties and their management in preschoolers with atopic eczema. Clin Exp Dermatol 1995; 20: 38–41
Dahl RE, Bernhisel-Broadbent J, Scanlon-Holdford S, et al. Sleep disturbances in children with atopic dermatitis. Arch Pediatr Adolesc Med 1995; 149: 856–60
Lewis-Jones MS, Finlay AY, Dykes PJ. The infants’ dermatitis quality of life index. Br J Dermatol 2001; 144: 104–10
Lapidus CS, Kerr PE. Social impact of atopic dermatitis. Med Health R I 2001; 84: 294–5
Fennessy M, Coupland S, Popay J, et al. The epidemiology and experience of atopic eczema during childhood: a discussion paper on the implications of current knowledge for health care, public health policy and research. J Epidemiol Community Health 2000; 54: 581–9
Stewart AW, Mitchell EA, Pearce N, et al. The relationship of per capita gross national product to the prevalence of symptoms of asthma and other atopic diseases in children (ISAAC). Int J Epidemiol 2001; 30: 173–9
Lamb SR, Rademaker M. Pharmacoeconomics of drug therapy for atopic dermatitis. Exp Opin Pharmacother 2002; 3: 249–55
Kernick D, Cox A, Powell R, et al. A cost consequence study of the impact of a dermatology-trained practice nurse on the quality of life of primary care patients with eczema and psoriasis. Br J Gen Pract 2000; 50: 555–8
Kemp AS. Atopic eczema: its social and financial costs. J Paediatr Child Health 1999; 35: 229–31
Resnick SD, Hornung R, Konrad TR. A comparison of dermatologists and generalists: management of childhood atopic dermatitis. Arch Dermatol 1996; 132: 1047–52
Lapidus CS, Schwarz DF, Honig PJ. Atopic dermatitis in children: who cares? who pays? J Am Acad Dermatol 1993; 28: 699–703
Ellis CN, Drake LA, Prendergast MM, et al. Cost of atopic dermatitis and eczema in the United States. J Am Acad Dermatol 2002; 46: 361–70
Herd RM, Tidman MJ, Prescott RJ, et al. The cost of atopic eczema. Br J Dermatol 1996; 135: 20–3
Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000; 4: 1–191
Khan SN, Slavin RG. Pediatricians’ attitudes towards allergy: past and present attitudes of pediatricians towards allergy. Ann Allergy Asthma Immunol 2000; 85: 189–93
Williams HC. Epidemiology of atopic dermatitis. Clin Exp Dermatol 2000; 25: 522–9
Marks R. The public health approach to the burden of common skin diseases in the community. J Dermatol 2001; 28: 602–5
Hammarstrom B, Wessling A, Nilsson JL. Pharmaceutical care for patients with skin diseases: a campaign year at Swedish pharmacies. J Clin Pharm Ther 1995; 20: 327–34
Shum KW, Lawton S, Williams HC, et al. The British Association of Dermatologists audit of atopic eczema management in secondary care. Phase 1: audit of service structure. Br J Dermatol 1999; 141: 430–7
Chinn DJ, Poyner T, Sibley G. Randomized controlled trial of a single dermatology nurse consultation in primary care on the quality of life of children with atopic eczema. Br J Dermatol 2002; 146: 432–9
Thomas KS, Armstrong S, Avery A, et al. Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema [abstract]. BMJ 2002; 324: 768–71
Cheer SM, Plosker GL. Tacrolimus ointment: a review of its therapeutic potential as a topical therapy in atopic dermatitis. Am J Clin Dermatol 2001; 2: 389–406
Wellington K, Jarvis B. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis. Drugs 2002; 62: 817–40
Reitamo S, Van Leent EJ, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002; 109: 539–46
Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J Am Acad Dermatol 2002; 46: 228–41
Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children [online]. Pediatrics 2002; 110: e2
Salek MS, Finlay AY, Luscombe DK, et al. Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis: a randomized, double-blind, placebo-controlled trial. Br J Dermatol 1993; 129: 422–30
Jang IG, Yang JK, Lee HJ, et al. Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma. J Am Acad Dermatol 2000; 42: 1033–40
Jolles S, Hughes J, Rustin M. The treatment of atopic dermatitis with adjunctive high-dose intravenous immunoglobulin: a report of three patients and review of the literature. Br J Dermatol 2000; 142: 551–4
Fischer G. Compliance problems in paediatric atopic eczema. Australas J Dermatol 1996; 37: S10–3
Jensen P. Use of alternative medicine by patients with atopic dermatitis and psoriasis. Acta Derm Venereol 1990; 70: 421–4
Ashcroft DM, Po AL. Herbal remedies: issues in licensing and economic evaluation. Pharmacoeconomics 1999; 16 (4): 321–8
Fung AY, Look PC, Chong LY, et al. A controlled trial of traditional Chinese herbal medicine in Chinese patients with recalcitrant atopic dermatitis. Int J Dermatol 1999; 38: 387–92
Worm M, Henz BM. Novel unconventional therapeutic approaches to atopic eczema. Dermatology 2000; 201: 191–5
Ohya Y, Williams H, Steptoe A, et al. Psychosocial factors and adherence to treatment advice in childhood atopic dermatitis. J Invest Dermatol 2001; 117: 852–7
Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000; 142: 931–6
Poysa L, Remes K, Korppi M, et al. Compliance with a dietary manipulation programme in families with infants prone to atopy. Acta Paediatr Scand 1988; 77: 563–8
Chandra RK. Five-year follow-up of high-risk infants with family history of allergy who were exclusively breast-fed or fed partial whey hydrolysate, soy, and conventional cow’s milk formulas. J Pediatr Gastroenterol Nutr 1997; 24: 380–8
Halken S, Hansen KS, Jacobsen HP, et al. Comparison of a partially hydrolyzed infant formula with two extensively hydrolyzed formulas for allergy prevention: a prospective, randomized study. Pediatr Allergy Immunol 2000; 11: 149–61
Pike MG, Carter CM, Boulton P, et al. Few food diets in the treatment of atopic eczema. Arch Dis Child 1989; 64: 1691–8
Tan BB, Weald D, Strickland I, et al. Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis. Lancet 1996; 347: 15–8
Schiffner R, Schiffner-Rohe J, Gerstenhauer M, et al. Differences in efficacy between intention-to-treat and per-protocol analyses for patients with psoriasis vulgaris and atopic dermatitis: clinical and pharmacoeconomic implications. Br J Dermatol 2001; 144: 1154–60
Acknowledgements
The author has acted as a consultant to CSL, manufacturers of intravenous immunoglobulin, and Novartis Pharmaceuticals, manufacturers of pimecrolimus.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kemp, A.S. Cost of Illness of Atopic Dermatitis in Children. Pharmacoeconomics 21, 105–113 (2003). https://doi.org/10.2165/00019053-200321020-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-200321020-00003